Cytokinetics to Announce Fourth Quarter Results on February 24, 2026

Core Insights - Cytokinetics is set to report its fourth quarter results on February 24, 2026, at 4:00 PM Eastern Time, followed by a conference call at 4:30 PM to discuss financial results and business updates [1][2] Company Overview - Cytokinetics is a specialty cardiovascular biopharmaceutical company with over 25 years of experience in muscle biology, focusing on developing new medicines for cardiac muscle dysfunction [3] - The company’s MYQORZO™ (aficamten) is approved for treating adults with symptomatic obstructive hypertrophic cardiomyopathy (HCM) and has received positive recommendations for marketing authorization in the European Union, with a decision expected in the first quarter of 2026 [3] - Cytokinetics is also developing omecamtiv mecarbil, an investigational cardiac myosin activator for heart failure with severely reduced ejection fraction, and ulacamten, an investigational cardiac myosin inhibitor for heart failure with preserved ejection fraction [3]